Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials ...

HUTCHMED divested a 45.0% equity interest in SHPL for $608.5 million in cash in April 2025, retaining a 5.0% equity interest. As a result, HUTCHMED’s share of equity in earnings of SHPL in 2025 ...

Maccreanor Lavington Architects has submitted plans for phase one of a long-awaited, 948-home scheme at Pudding Mill Lane, east London ...

When WSDOT closed two lanes of the northbound 1st Avenue South Bridge after an inspection revealed problems 2+ weeks ago, an update was promised by this Friday. Today, we have it - a repair plan ...

The Premier League outfit have won their last three Champions League round of 16 ties and 13 of their last 16 UEFA two-legged ties. This is the first ever European Cup/Champions League two-legged tie ...

Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...

The only approved gene therapy for RP today targets a single gene RPE65, which accounts for just 1% to 2% of the total RP patient population. We believe OCU400 has significantly wider commercial ...

Eyepoint Pharmaceuticals (NASDAQ:EYPT) outlined late-stage clinical progress for its lead retinal candidate DURAVYU and ...

A few months into GLP-1 treatment, many patients encounter an unexpected and distressing side effect: significant hair loss.